N/A N=390 Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Intumescent Cataract
Primary: Percentage of Capsular Tears (Anterior or Posterior) During Surgery — 5.3; 5.3 percentage of capsular tears
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Quatera 700 vs. Centurion
Cataract
Primary: Central Corneal Thickness — 572.8; 565.6 microns
N/A N=94 Femtosecond Laser Assisted Keratotomies for the Management of Corneal Astigmatism
Astigmatism · Cataract
Primary: Keratometric Correction Index — 0.51 index
N/A N=114 Infant Aphakia Treatment Study (IATS)
Congenital Cataract
Primary: Visual Acuity — 0.80; 0.97 logMAR units — p=0.19
N/A N=108 Next Generation Cataract Surgery Study
Cataract
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Anterior Segment Surgical Functionality Perform Per the Intended Use as Defined in Protocol Section…
Phase 3 N=1,020 Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)
Cataract
Primary: Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up — 227; 255 participants — p=0.03
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 3 N=122 One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction
Aphakia · Cataract
Primary: Visual Acuity — 108 Participants
Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
N/A N=505 Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery
Primary Open Angle Glaucoma (POAG) · Cataract
Primary: Proportion of Eyes With ≥ 20% Decrease in Intraocular Pressure (IOP) From Baseline to the Hypotensive Medication-free 24-month Postoperative Examination Using…
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
N/A N=110 Infrared Choroidal Reflectance Camera for the Detection of Childhood Cataract
Childhood Cataract
Primary: Results of Red-reflex and Infrared-reflex Tests Compared to Gold Standard — 17; 54; 32; 7 eyes
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
N/A N=118 Next Generation Cataract and Vitreoretinal Surgery Study
Vitreoretinal Disease With or Without Cataracts
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Using Vitreoretinal or Combined Surgical Functionality Perform Per the Intended Use as Defined in…
N/A N=100 Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
Capsule Opacification · Pseudophakia · Cataract
Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)
Phase 2 N=30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants
Phase 4 N=79 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
Phase 3 N=299 Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
Pain · Inflammation
Primary: Summed Ocular Inflammation Score (SOIS) of Zero — 70; 36 participants
N/A N=100 Assessment of Low Energy Lens Fragmentation Cataract Extraction in Patients Undergoing Cataract Surgery
Cataract
Primary: Total Lens Removal Time — 76.0; 80.1 seconds
N/A N=130 Cataract Surgery: Femto LDV Z8 Versus Conventional
Cataract
Primary: Effective Phaco Time (EPT) — 1.48; 2.3 EPT
N/A N=104 Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
Cataract
Primary: Posterior Capsule Opacification (PCO) — 11.58; 14.04 Percentage of PCO
Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
N/A N=3,785 Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313
Posterior Capsule Opacification
Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes
Phase 3 N=60 Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery
Cataract
Primary: Deviation From Intended Capsulotomy Diameter — 26.8; 339.1 μm
N/A N=400 Clinical Evaluation of a New Viscoelastic for Cataract Surgery
Cataract
Primary: Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively — 10.6; 7.6 percentage of participants